Scott North on Muck Rack

Scott North

Everett
As seen in: JAMA Oncology, The Seattle Times, Washington Times, The Charlotte Observer, The Spokesman-Review, Lexington Herald-Leader, Fort Worth Star-Telegram, The News & Observer, Tacoma News Tribune, The Columbian and
Personal account of former journalistic outdoor dog at @everettherald
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Scott

Contact Scott, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study

|
By Patrick Cheung, Samir H. Patel, Scott North, Arjun Sahgal
| European Urology Verified
Abstract Background Despite the paucity of prospective evidence, stereotactic radiotherapy (SRT) is increasingly being considered in the setting of oligoprogression to delay the need to change systemic therapy.
Open in Who Shared Issue with article?

Patterns of cost-related medication underuse among Canadian adults with cancer: a cross-sectional study using survey data

|
By Omar Abdel-Rahman, Scott North
| cmajopen.ca
Research Open Access Omar Abdel-Rahman and Scott North May 06, 2021 9 (2) E474-E481; DOI: https://doi.org/10.9778/cmajo.20200186 Abstract Background: Cost-related medication underuse (CRMU) has been reported within the general population in Canada. In this study, we assessed patterns of CRMU among Canadian adults with cancer. Methods: This is a cross-sectional study using survey data.
Open in Who Shared Issue with article?

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer

|
By Srikala S. Sridhar, Ben Tran, M. Neil Reaume, Scott North
| JAMA Oncology Verified
[Skip to Content Landing] Original Investigation September 17, 2020 JAMA Oncol. 2020;6(11):1751-1758. doi:10.1001/jamaoncol.2020.3927 Full Text Key Points Question In patients with platinum-refractory metastatic urothelial cancer, is nab-paclitaxel more effective and better tolerated than paclitaxel?
Open in Who Shared Issue with article?
See all 791 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified